Login to Your Account



Clinic Roundup


Wednesday, June 20, 2012
• NewLink Genetics Corp., of Ames, Iowa, has passed the midpoint in enrollment in its Phase III hyperacute pancreas immunotherapy product candidate (algenpantucel-L) trial with full enrollment projected to be completed by the end of 2013.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription